Fulcrum Therapeutics completes enrollment in Phase 3 trial of losmapimod in FSHD

Fulcrum Therapeutics has completed enrollment in REACH, a Phase 3 clinical trial evaluating losmapimod in patients with FSHD at sites in the United States, Canada, and Europe. Topline data expected in the fourth quarter of 2024. REACH is a Phase 3 multi-center, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of losmapimod for the treatment of FSHD. Results reported from the Phase 2b ReDUX4 trial demonstrated slowed disease progression and improved function. Losmapimod has been granted FDA Fast Track designation and Orphan Drug Designation for the treatment of FSHD.